SARS-CoV-2 Omicron neutralization and risk of infection among elderly after a booster dose of Pfizer vaccine

Timothee Bruel; Laurie Pinaud; Laura Tondeur; Delphine Planas; Isabelle Staropoli; Francoise Porrot; Florence Guivel-Benhassine; Mikael Attia; Stephane Pelleau; Tom Woundenberg; Cecile Duru; Aymar Davy Koffi; Sandrine Castelain; Sandrine Fernandes-Pellerin; Nathalie Jolly; Louise Perrin de Facci; Emmanuel Roux; Marie-Noelle Ungeheuer; Sylvie Van Der Werf; Michael White; Olivier Schwartz; Arnaud Fontanet.
Preprint en Inglés | PREPRINT-MEDRXIV | ID: ppmedrxiv-22273175

Documentos relacionados

  1. Neutralising antibody responses to SARS-CoV-2 omicron among elderly nursing home residents following a booster dose of BNT162b2 vaccine: A community-based, prospective, longitudinal cohort study.
  2. T cell responses to SARS-CoV-2 spike cross-recognize Omicron.
  3. Antibody Avidity Maturation Following Recovery From Infection or the Booster Vaccination Grants Breadth of SARS-CoV-2 Neutralizing Capacity.
  4. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization.
  5. Immunity of Heterologously and Homologously Boosted or Convalescent Individuals Against Omicron BA.1, BA.2, and BA.4/5 Variants.
  6. Infection with wild-type SARS-CoV-2 elicits broadly neutralizing and protective antibodies against omicron subvariants.
  7. The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic.
  8. Infection and Vaccine Induced Spike Antibody Responses Against SARS-CoV-2 Variants of Concern in COVID-19-Naïve Children and Adults.
  9. SARS-CoV-2 Antibody Response After a Third Dose of the BNT162b2 Vaccine in Patients Receiving Maintenance Hemodialysis or Peritoneal Dialysis.
  10. Trends of humoral immune responses to heterologous antigenic exposure due to vaccination & omicron SARS-CoV-2 infection: Implications for boosting.